Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

Sponsor
Al-Azhar University
Study ID
NCT06759077
Phase
PHASE3
Status
Active Not Recruiting

Conditions

  • Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months

Study Details

If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life

Key Dates

Start date
Dec 28, 2024
Status verified
Jan 2025
Primary completion
Dec 28, 2024
Completion
Dec 28, 2025

Study Design

Enrollment
126 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • No Intervention: standard treatment
    Adult patients with advanced CKD who will take the standard treatment for 6months.
  • Experimental: interventional Group
    adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months

Primary Outcome Measure

Investigate the cardio protective effect of SGL2 inhibitors(DAPAGLIFLOZINE (10 mg/day)) in dialysis patients ,by measuring human N terminal pro brain natriuretic peptide (N -pro BNB) at baseline and after 6months [ Time Frame: up to 24 weeks ]

Related Studies